On March 24, 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported it will present a poster entitled ‘Preclinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies’ on 12 April 2022 at the forthcoming hybrid American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place inNew Orleans, US on 8-13 April 2022 (Press release, Redx Pharma, MAR 24, 2022, View Source [SID1234610843]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will present preclinical data on the potential benefits of RXC004, Redx’s lead oncology asset, in combination with clinically relevant standard of care chemotherapy regimens. RXC004 is a potent, orally active porcupine inhibitor in clinical development as a targeted therapy for Wnt-ligand driven cancer. It is currently in Phase 1 clinical studies in combination with nivolumab, an anti-PD-1 antibody, and is also being evaluated as a monotherapy in Phase 2 proof-of-concept clinical studies for the treatment of genetically selected pancreatic cancer, genetically selected metastatic colorectal cancer and unselected biliary cancer.
Title: Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies
Abstract: 2566
Day/Date: Tuesday 12 April 2022
Session name and category: PO.ET06.09-Cell Cycle, Replication Inhibitors, and Immunotherapy Agents
The abstract is available via the AACR (Free AACR Whitepaper) Annual Meeting website at:View Source!/10517/presentation/15373
The poster will be available from Friday 8 April on the AACR (Free AACR Whitepaper) e-poster website and the investor section of the Company’s website at: View Source